跳至主要内容
临床试验/NL-OMON47485
NL-OMON47485已完成不适用

Morphine for palliative treatment of refractory dyspnea in patients with advanced COPD: benefits and respiratory adverse effects - MORDYC

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 124 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
124

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * diagnosis of COPD according to the current Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD);;* optimal pharmacological treatment including treatment with a combination of a long-acting muscarinic antagonist and an ultra-long-acting *-agonist; ;* Grade 2, 3 or 4 dyspnea on the mMRC; ;* optimal non-pharmacological treatment defined as completed a comprehensive pulmonary rehabilitation program

排除标准

  • * history of substance misuse;
  • * exacerbation of COPD within two weeks of study enrolment;
  • * waiting list for lung transplantation;
  • * pregnant or childbearing potential not using contraception;
  • * renal failure (creatinine clearance <15mL/min);
  • * age under 18
  • * not being able to read or fill in the questionnaires or diary
  • * allergy for morphine or its excipients
  • * concomitant use of irreversible MAO blockers
  • * use of opioids
  • * history of convulsions
  • * head injury
  • * intestinal obstruction
  • * gastroparesis
  • * liver disease

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验